A detailed history of Walleye Trading LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Walleye Trading LLC holds 16,078 shares of RVNC stock, worth $41,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,078
Previous 19,700 18.39%
Holding current value
$41,320
Previous $173,000 54.34%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.65 - $9.31 $124,127 - $248,521
-26,694 Reduced 62.41%
16,078 $79,000
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $175,403 - $338,128
30,190 Added 239.95%
42,772 $375,000
Q3 2023

Nov 14, 2023

BUY
$11.47 - $25.07 $143,088 - $312,748
12,475 Added 11658.88%
12,582 $144,000
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $329,621 - $501,905
-13,345 Reduced 99.2%
107 $2,000
Q1 2023

May 15, 2023

SELL
$18.36 - $35.27 $268,625 - $516,035
-14,631 Reduced 52.1%
13,452 $433,000
Q4 2022

Feb 14, 2023

SELL
$18.32 - $30.66 $1.42 Million - $2.38 Million
-77,605 Reduced 73.43%
28,083 $518,000
Q3 2022

Nov 14, 2022

BUY
$14.33 - $28.47 $987,193 - $1.96 Million
68,890 Added 187.21%
105,688 $2.85 Million
Q2 2022

Aug 08, 2022

SELL
$11.52 - $20.4 $695,831 - $1.23 Million
-60,402 Reduced 62.14%
36,798 $509,000
Q1 2022

May 16, 2022

BUY
$12.36 - $20.31 $1.04 Million - $1.72 Million
84,480 Added 664.15%
97,200 $1.9 Million
Q4 2021

Feb 14, 2022

BUY
$12.46 - $27.87 $34,003 - $76,057
2,729 Added 27.31%
12,720 $208,000
Q2 2021

Aug 16, 2021

BUY
$26.8 - $31.84 $267,758 - $318,113
9,991 New
9,991 $296,000
Q4 2018

Feb 14, 2019

SELL
$18.06 - $24.96 $388,308 - $536,664
-21,501 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$23.55 - $30.1 $154,535 - $197,516
6,562 Added 43.93%
21,501 $534,000
Q2 2018

Aug 14, 2018

BUY
$27.45 - $33.35 $410,075 - $498,215
14,939 New
14,939 $410,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.